Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households
- PMID: 12447733
- DOI: 10.1086/345722
Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households
Abstract
A double-blind, randomized study of inhaled zanamivir for the prevention of influenza in families was conducted. Once a person with a suspected case of influenza was identified (index patient), treatment of all other household members (contacts) > or =5 years old was initiated. Contacts received either 10 mg zanamivir or placebo inhaled once daily for 10 days. Index patients received relief medication only. In total, 487 households (242 placebo and 245 zanamivir) were enrolled, with 1291 contacts randomly assigned to receive prophylaxis. Four percent of zanamivir versus 19% of placebo households (P<.001) had at least 1 contact who developed symptomatic, laboratory-confirmed influenza, representing 81% protective efficacy (95% confidence interval, 64%-90%). Protective efficacy was similarly high for individuals (82%) and against both influenza types A and B (78% and 85%, respectively, for households). Zanamivir was well tolerated and was effective in preventing influenza types A and B within households where the index patient was not treated.
Similar articles
-
Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8. doi: 10.1016/j.clinthera.2007.08.023. Clin Ther. 2007. PMID: 17919541 Clinical Trial.
-
Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.Med Microbiol Immunol. 2002 Dec;191(3-4):169-73. doi: 10.1007/s00430-002-0140-3. Epub 2002 Sep 11. Med Microbiol Immunol. 2002. PMID: 12458354 Review.
-
Zanamivir: from drug design to the clinic.Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1885-93. doi: 10.1098/rstb.2001.1021. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11779388 Free PMC article. Review.
-
Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.N Engl J Med. 2000 Nov 2;343(18):1282-9. doi: 10.1056/NEJM200011023431801. N Engl J Med. 2000. PMID: 11058672 Clinical Trial.
-
Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.J Infect. 2000 Jan;40(1):42-8. doi: 10.1053/jinf.1999.0602. J Infect. 2000. PMID: 10762110 Clinical Trial.
Cited by
-
A Malaysian consensus recommendation for the prevention of influenza in older persons.BMC Infect Dis. 2022 Dec 15;22(1):943. doi: 10.1186/s12879-022-07920-3. BMC Infect Dis. 2022. PMID: 36522615 Free PMC article.
-
Randomization for the susceptibility effect of an infectious disease intervention.J Math Biol. 2022 Sep 20;85(4):37. doi: 10.1007/s00285-022-01801-8. J Math Biol. 2022. PMID: 36127558 Free PMC article.
-
Antiviral Drugs in Influenza.Int J Environ Res Public Health. 2022 Mar 4;19(5):3018. doi: 10.3390/ijerph19053018. Int J Environ Res Public Health. 2022. PMID: 35270708 Free PMC article. Review.
-
Household transmission of influenza A and B within a prospective cohort during the 2013-2014 and 2014-2015 seasons.Stat Med. 2021 Dec 10;40(28):6260-6276. doi: 10.1002/sim.9181. Epub 2021 Sep 27. Stat Med. 2021. PMID: 34580901 Free PMC article.
-
Understanding the Impact of Resistance to Influenza Antivirals.Clin Microbiol Rev. 2021 Feb 10;34(2):e00224-20. doi: 10.1128/CMR.00224-20. Print 2021 Mar 17. Clin Microbiol Rev. 2021. PMID: 33568554 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
